Morgan Stanley analysts are setting a bullish tone for the upcoming earnings season, with specific companies expected to outperform. According to the analysts, investors should watch Amazon (NASDAQ:AMZN), Apple (NASDAQ:AAPL), and Eli Lilly (NYSE:LLY) closely, as these companies are anticipated to deliver strong results. Amazon is highlighted with a "Positive" near-term view. Morgan Stanley expects Amazon to deliver a significant EBIT beat in Q2 and guide positively for Q3. "We are 17% above Street EBIT" for Q2 and 10% above for Q3, the analysts noted, driven by North America Retail profitability and accelerating growth in Amazon Web Services (AWS). Apple also holds a "Positive" near-term outlook. For the first time in over a year, Morgan Stanley sees a favorable setup, expecting Apple to post better-than-expected results. "Street estimates are 4-5% too low for the September quarter," the analysts stated. They forecast Apple will achieve $96.9 billion in revenue for the September quarter, which is 4% above the consensus. Driving this optimism are strong iPhone builds, improvements in the Mac outlook, and robust growth in Services. Eli Lilly is another key player with a positive outlook. Morgan Stanley anticipates that upcoming data from the Phase 3 SUMMIT trial of Tirzepatide/Zepbound in patients with obesity and heart failure will be a catalyst for the stock. The data, expected in Q3, could demonstrate significant benefits beyond weight loss, potentially broadening Medicare coverage and strengthening Tirzepatide's competitive profile. The analysts noted, "We would expect positive data from SUMMIT (a statistically significant benefit on CV outcomes) to move LLY shares up ~2-3%." Overall, Morgan Stanley's analysts are keen to see how companies manage margins in a challenging pricing environment and whether high expectations for the second half of 2024 will hold. They also highlighted that earnings revisions for the S&P 500 have been less negative than average heading into the reporting season, suggesting cautious optimism for the broader market. Related Articles Amazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbook Abbott posts Q2 earnings beat, lifts full-year outlook Citi sees further S&P 500 upside during 2H24
Amazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...